Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). (Q34267478)

1 August 2017

title

Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). (English)

1 reference

1 August 2017

1 reference

Carl E Frasch

1 reference

1 August 2017

author name string

Marie-Pierre Preziosi

series ordinal

1 reference

1 August 2017

F Marc LaForce

series ordinal

1 reference

1 August 2017

publication date

12 April 2012

1 reference

Human Vaccines & Immunotherapeutics

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

715-724

1 reference

The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005.

1 August 2017

cites work

1 reference

Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine

21 January 2018

1 reference

Human immunity to the meningococcus. I. The role of humoral antibodies

21 January 2018

1 reference

THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS

21 January 2018

1 reference

Human immunity to the meningococcus. II. Development of natural immunity

21 January 2018

1 reference

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

21 January 2018

1 reference

The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man.

21 January 2018

1 reference

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution

21 January 2018

1 reference

The epidemiology of meningococcal disease in India

21 January 2018

1 reference

Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine

21 January 2018

1 reference

Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges

21 January 2018

1 reference

Product Development Partnerships Hit Their Stride: Lessons From Developing A Meningitis Vaccine For Africa

21 January 2018

1 reference

Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses

21 January 2018

1 reference

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa

21 January 2018

1 reference

Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid

21 January 2018

1 reference

Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide

21 January 2018

1 reference

Determination of hydrazine in a meningococcal C conjugate vaccine intermediary product

21 January 2018

1 reference

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

21 January 2018

1 reference

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans

21 January 2018

1 reference

Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4161/HV.19619

1 reference

1 August 2017

1 reference